Sydney, 25 June 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to invite shareholders to attend information briefing sessions to discuss the company’s recent activities.
Shareholder briefing sessions:
The following sessions are available to those shareholders able to attend:
Melbourne
Monday 16 July, 5:30 – 7:30 pm
Baker McKenzie offices
Level 19, 181 William Street
Melbourne
Sydney
Wednesday 18 July, 5:30 – 7:30 pm
Baker McKenzie offices,
Tower 1, level 46, 100 Barangaroo Avenue
Sydney
Shareholders wishing to register interest in attending one of the above events should RSVP by COB Tuesday, 10 July via the Kazia website, using the following link: https://www.kaziatherapeutics.com/common/contactus. At the time of RSVP, please note your: name, email, contact number and which briefing session is of interest (Sydney or Melbourne.)
Shareholders are invited to submit questions ahead of the event for discussion during the session. To submit a question, please visit https://www.kaziatherapeutics.com/common/contactus and enter your question by close of business on Friday 13 July.
The Kazia team looks forward to seeing those shareholders who are able to attend.
Briefing webcast and Q+A session:
For those shareholders unable to attend the briefing sessions in person, Kazia will make available via its website a webcast of the Sydney shareholder briefing session within a few days of the event.
[ENDS]
Board of Directors
Mr Iain Ross Chairman, Non-Executive Director
Mr Bryce Carmine Non-Executive Director
Mr Steven Coffey Non-Executive Director
Dr James Garner Chief Executive Officer, Managing Director
Media and investor relations
Glen Zurcher
E: glen.zurcher@irdepartment.com.au
T: +61 420 249 299
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer. Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial in March 2018. Initial data is expected in early calendar 2019.
TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data was presented in June 2018 and the study remains ongoing.
For more information, please visit www.kaziatherapeutics.com.
